Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$4.51 USD
+0.32 (7.64%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $4.51 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
AVXL 4.51 +0.32(7.64%)
Will AVXL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AVXL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AVXL
Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
AVXL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to Trade
Other News for AVXL
Acadia Pharmaceuticals: Back In The Buy Zone
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Eli Lilly And Alzheimer's Disease: The Paucity Of Progress
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Akero Therapeutics (AKRO)
Lilly's donanemab, remternetug set to dominate Alzheimer's treatment by 2030